Biogen Inc. (BIIB): Price and Financial Metrics


Biogen Inc. (BIIB): $331.93

6.53 (+2.01%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add BIIB to Watchlist
Sign Up

Industry: Biotech


Ranked

of 495

in industry

BIIB POWR Grades


  • BIIB scores best on the Value dimension, with a Value rank ahead of 98.05% of US stocks.
  • The strongest trend for BIIB is in Quality, which has been heading down over the past 31 weeks.
  • BIIB ranks lowest in Momentum; there it ranks in the 5th percentile.

BIIB Stock Summary

  • Biogen Inc's market capitalization of $48,495,482,352 is ahead of 94.63% of US-listed equities.
  • Biogen Inc's stock had its IPO on September 17, 1991, making it an older stock than 82.79% of US equities in our set.
  • Of note is the ratio of Biogen Inc's sales and general administrative expense to its total operating expenses; merely 17.7% of US stocks have a lower such ratio.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Biogen Inc are JCI, NEM, PHG, TEL, and SNP.
  • Visit BIIB's SEC page to see the company's official filings. To visit the company's web site, go to www.biogen.com.

BIIB Valuation Summary

  • In comparison to the median Healthcare stock, BIIB's price/sales ratio is 65.4% lower, now standing at 4.1.
  • BIIB's EV/EBIT ratio has moved down 53.8 over the prior 243 months.
  • Over the past 243 months, BIIB's price/sales ratio has gone down 40.7.

Below are key valuation metrics over time for BIIB.

Stock Date P/S P/B P/E EV/EBIT
BIIB 2014-08-28 9.7 8.4 37.7 27.1
BIIB 2014-03-31 10.4 8.4 38.8 29.3
BIIB 2007-12-07 7.4 4.4 40.3 29.0
BIIB 2003-08-07 11.4 4.3 31.5 20.7
BIIB 2002-12-13 14.1 5.2 38.7 26.2
BIIB 2001-08-31 42.2 11.4 116.7 72.5

BIIB Growth Metrics

  • The 4 year net income to common stockholders growth rate now stands at 59.09%.
  • Its year over year net cashflow from operations growth rate is now at -50.17%.
  • The year over year cash and equivalents growth rate now stands at -53.02%.
Over the past 33 months, BIIB's revenue has gone down $1,535,900,000.

The table below shows BIIB's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 11,697.7 2,810.3 1,918.1
2021-03-31 12,604.3 3,531.5 3,011.7
2020-12-31 13,444.6 4,229.8 4,000.6
2020-09-30 14,263.3 6,557.1 5,082.4
2020-06-30 14,487.3 7,070.9 5,926.8
2020-03-31 14,422.4 7,086.4 5,878.8

BIIB Price Target

For more insight on analysts targets of BIIB, see our BIIB price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $404.08 Average Broker Recommendation 1.67 (Moderate Buy)

BIIB Stock Price Chart Interactive Chart >

Price chart for BIIB

BIIB Price/Volume Stats

Current price $331.93 52-week high $468.55
Prev. close $325.40 52-week low $223.25
Day low $322.51 Volume 1,269,800
Day high $335.00 Avg. volume 1,587,810
50-day MA $335.18 Dividend yield N/A
200-day MA $282.22 Market Cap 49.47B

Biogen Inc. (BIIB) Company Bio


Biogen discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders. The company was founded in 1985 and is based in Cambridge, Massachusetts.


BIIB Latest News Stream


Event/Time News Detail
Loading, please wait...

BIIB Latest Social Stream


Loading social stream, please wait...

View Full BIIB Social Stream

Latest BIIB News From Around the Web

Below are the latest news stories about Biogen Inc that investors may wish to consider to help them evaluate BIIB as an investment opportunity.

Could These 3 Potential Blockbusters Transform Biogen?

Biogen's (NASDAQ: BIIB) earnings report last week offered us a clear picture of why the biotech company is in need of a change. CEO Michel Vounatsos says the company is in the process of becoming not just an MS company -- but a full neuroscience company. Biogen recently reported positive data from a pivotal phase 3 trial investigating zuranolone for major depressive disorder (also known as clinical depression).

Yahoo | July 25, 2021

Biogen Inc. (NASDAQ:BIIB) Insiders Increased Their Holdings

We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...

Yahoo | July 25, 2021

Biogen Inc. 2021 Q2 - Results - Earnings Call Presentation

The following slide deck was published by Biogen Inc. in conjunction with their 2021 Q2 earnings call....

SA Transcripts on Seeking Alpha | July 23, 2021

Biogen to Present Data from ADUHELM and Alzheimer’s Disease Portfolio at 2021 Alzheimer’s Association International Conference

CAMBRIDGE, Mass., July 23, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced it will share multiple oral and poster presentations from its Alzheimer’s disease clinical development portfolio at the Alzheimer’s Association International Conference (AAIC), which will be held in Denver, Colorado and online July 26-30, 2021. The company’s contributions to AAIC will include several presentations highlighting data on ADUHELM™ (aducanumab-avwa) injection 100 mg/mL solution, which was r

Yahoo | July 23, 2021

Biogen Defends Controversial Alzheimer's Drug as FDA Calls for Probe

Biogen's new — and controversial — Alzheimer's drug, Adhulem, made a modest $2 million in revenue in the first several weeks after its...

Yahoo | July 23, 2021

Read More 'BIIB' Stories Here

BIIB Price Returns

1-mo -4.60%
3-mo 24.04%
6-mo 23.91%
1-year 15.98%
3-year -2.49%
5-year 24.68%
YTD 35.56%
2020 -17.48%
2019 -1.39%
2018 -5.54%
2017 21.96%
2016 -7.43%

Continue Researching BIIB

Want to see what other sources are saying about Biogen Inc's financials and stock price? Try the links below:

Biogen Inc (BIIB) Stock Price | Nasdaq
Biogen Inc (BIIB) Stock Quote, History and News - Yahoo Finance
Biogen Inc (BIIB) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8067 seconds.